Skip to main content

Table 2 Sample characteristics

From: “‘You lose your hair, what’s the big deal?’ I was so embarrassed, I was so self-conscious, I was so depressed:” a qualitative interview study to understand the psychosocial burden of alopecia areata

Sample characteristic N (%)(N = 45)
Years since diagnosis, mean [range] 11.8 [1–47]
SALT scorea, mean [range] 67.2 [0–100]
Current treatment, n (%)b
 JAKi 15 (33)
 Other treatment(s) 7 (16)
 Unknown, either JAKi or placeboc 2 (4)
 No treatment 23 (51)
Gender, n (%)
 Male 19 (42)
 Female 26 (58)
Age, mean [range] 33.3 [15–72]
Ethnicity/race, n (%)
 Asian 9 (20)
 Black or African American 2 (4)
 White 25 (56)
 Hawaiian or Pacific Islander 1 (2)
 Hispanic 5 (11)
 Other 3 (7)
Country, n (%)
 United States 42 (93)
 Canada 3 (7)
Education, highest certificate achieved
 No high school diploma 9 (20)
 High school diploma or equivalent 15 (33)
 Associate’s degree 2 (4)
 Bachelor’s degree or higher 19 (42)
  1. Abbreviations: JAKi Janus kinase inhibitors, for example tofacitinib, SALT Severity of Alopecia Tool
  2. aSALT scores were clinician-reported and were calculated within a mean 0.6 months of the interview (range 0–7 months)
  3. bNon-mutually exclusive. Other treatments include Biotin Forte with zinc (n = 1), Clobetasol 0.05% ointment (n = 2), Diphenylcyclopropenone (n = 2), Excimer (n = 1), Intralesional Kenalog (n = 3), Luxiq foam (n = 1), Rogaine (n = 1), Slow-release iron (n = 1), Vitamin E (n = 1)
  4. cTwo patients were in a clinical trial and it was unknown if they were receiving JAKi or placebo
  5. Note: due to rounding some percentages may not total 100%